Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients

Neurologia i Neurochirurgia Polska

Volumn 43, Issue 2, 2009, Pages 126-133

  Sienkiewicz Jarosz, Halina ^a   Gałecka Walska, Maria ^a   Bidziński, Andrzej ^a   Turzyńska, Danuta ^a   Sobolewska, Alicia ^a   Lipska, Beata ^a   Płaźnik, Adam ^a   Ryglewicz, Danuta ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Biochemical markers; Excitatory amino acids; Functional outcome; GABA; Ischaemic stroke

Indexed keywords

4 AMINOBUTYRIC ACID; C REACTIVE PROTEIN; D DIMER; EXCITATORY AMINO ACID; NEURON SPECIFIC ENOLASE; PROTEIN S100B;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BRAIN DAMAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE MARKER; ENZYME BLOOD LEVEL; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; RANKIN SCALE;

AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; EXCITATORY AMINO ACIDS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; NERVE GROWTH FACTORS; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; S100 PROTEINS; STROKE;

EID: 67649090627     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Abraha H.D., Butterworth R.J., Bath P.M., et al. Serum S-100 protein, relationship to clinical outcome in acute stroke, Ann Clin Biochem 1997; 34: 366-370.
2. Herrmann M., Ebert A.D., Galazky I., et al. Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue. Stroke 2000; 31: 645-650.
3. Missler U., Wiesmann M., Freiedrich C, et al. S-100 protein and neuron-specific encase concenrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997; 28: 1956-1960.
4. Wunderlich M.T., Ebert A.D., Kratz T., et al. Farly neurobehavioral outcome after stroke is related to release of neurobiochemical marker of brain damage. Stroke 1999; 30: 1190-1195.
5. Weglewski A., Ryglewicz D., Mular A, et al. Zmiany stezenia bialka S100B w surowicy krwi W udarze niedokrwiennym i krwotocznym mózgu w zaleiności od wielkości ogniska udarowego. Neurol Neurochir Pol 2005; 39: 310-317.
6. Petzold A., Michel P, Stock M., et al. Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome. J Stroke Cerebrovasc Dis 2008; 17: 196-203.
7. Schoerkhuber W, Kittler H., Sterz F., et al. Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac-arrest. Stroke 1999; 30: 1598-1603.
8. Anand N., Stead L.G. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc Dis 2005; 20: 213-219.
9. Foerch C., Otto B., Singer O.C., et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004; 35: 2160-2164.
10. Foerch C., Singer O.C., Neumann-Haefelin T., et al. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005; 62: 1130-1134.
11. Mussack T., Hauser C., Klauss V., et al. Serum S100B protein levels during and after successful carotid artery stenting or carotid endarterectomy. J Endovasc Ther 2006; 13: 39-46.
12. Foerch C., Wunderlich M.T, Dvorak F., et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007; 38: 2491-2495.
13. Di Napoli M., Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32: 917-924.
14. Di Napoli M., Papa F.; Villa Pini Stroke Data Bank Investigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002; 33: 1763-1771.
15. Tsimikas S., Willerson J.T., Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006; 47 (8 Suppl): C19-31.
16. Purroy E, Montaner J., Molina C.A., et al. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke 2007; 38: 3225-3229.
17. Castillo J., Dávalos A., Naiveiro J., et al. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit an ischemic stroke. Stroke 1996; 27: 1060-1065.
18. Castillo J., Dávalos A., Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 1997; 349: 79-83.
19. Serena J., Leira R., Castillo J., et al. Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke 2001; 32: 1154-1161.
20. Dávalos A., Shuaib A., Wahlgren N.G. Neurotransmitters and pathophysiology of stroke: evidence for the release of glutamate and other transmitters/mediators in animals and humans. J Stroke Cerebrovasc Dis 2000; 9: 2-8.
21. Berger Ch., Schäbitz W., Georgiadis D., et al. Effects of hypothermia on excitatory amino acids and metabolism in stroke patients: a microdialysis study. Stroke 2002; 33: 519-534.
22. Stern P., Bartos V., Uhrova J., et al. Performance characteristics of seven neuron-specific enolase assays. Tumour Biol 2007; 28: 84-92.
23. Maciejak P., Lehner M., Turzyńska D., et al. The opposite role of hippocampal mGluR1 in fear conditioning in kindled and non-kindled rats. Brain Res 2008; 1187: 184-193.
24. Goldstein L.B., Bertels C., Davis J.N. Interrater reliability of the NIH stroke scale. Arch Neurol 1989; 46: 660-662.
25. Mahoney F.I., Barthel D. Functional evaluation: the Barthel Index.
26. Wunderlich M.T., Wallesch C.W., Goertler M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci 2004; 227: 49-53.
27. Alvarez-Sabín J., Molina C.A., Montaner J., et al. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients. Stroke 2003; 34: 1235-1241.
28. Gilmore R.M., Stead L.G. The role of hyperglycemia in acute ischemic stroke. Neurocrit Care 2006; 5: 153-158.
29. Ribo M., Molina C.A., Delgado P., et al. Hyperglycemia during ischemia rapidly accelerates brain damage in stroke patients treated with tPA. J Cemb Blood Flow Metab 2007; 27: 1616-1622.
30. Selakovic V., Raicevic R., Radenovic L. The increase of neuron-specific enolase in cerebrospinal fluid and plasma as a marker of neuronal damage in patients with acute brain infarction. J Clin Neurosci 2005; 12: 542-547.
31. Wunderlich M.T., Lins H., Skalej M., et al. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 2006; 108: 559-563.
32. Winbeck K., Poppert H., Etgen T., et al. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002; 33: 2459-2464.
33. Rallidis L.S., Vikelis M., Panagiotakos D.B., et al. Usefulness of inflammatory and haemostatic markers to predict short-term risk for death in middle-aged ischaemic stroke patients. Acta Neurol Scand 2008; 117: 415-420.
34. Topakian R., Strasak A.M., Nussbaumer K., et al. Prognostic value of admission C-reactive protein in stroke patients undergoing iv thrombolysis. J Neurol 2008; 255: 1190-1196.
35. Barber M., Langhorne P., Rumley A., et al. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke 2004; 35: 1421-1425.
36. Barber M., Langhorne P., Rumley A., et al. D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays. Stroke 2006; 37: 1113-1115.
37. Ageno W, Finazzi S., Steidl L., et al. Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med 2002; 162: 2589-2593.
38. Squizzato A., Ageno W. D-amer testing in ischemic stroke and cerebral sinus and venous thmmbosis. Semin Vasc Med 2005; 5: 379-386.
39. Triage Stroke Panel Product Insert, Biosite Inc, 2005.
40. Koch H.J., Horn M., Bogdahn U., et al. The relationship between plasma D-dimer concentrations and acute ischemic stroke subtypes. J Stroke Cerebrovasc Dis 2005; 14: 75-79.
41. Laskowitz D.T., Kasner S.E., Saver J., et al. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 2009; 40: 77-85.
42. Montaner J., Perea-Gainza M., Delgado P., et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008; 39: 2280-2287.
43. Haapaniemi E., Tatlisumak T. Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol Scand 2009; 119: 141-150.
44. Squizzato A., Ageno W., Finazzi S., et al. D-dimer is not a long-term prognostic marker following acute cerebral ischemia. Blood Coagal Fibrinolysis 2006; 17: 303-306.
45. Pieper C.F., Rao K.M., Currie M.S., et al. Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons. J Gerontol A Biol Sci Med Sci 2000; 55: M649-657.
46. Kelly J., Rudd A., Lewis R.R., et al. The relationship between acute ischaemic stroke and plasma D-dimer levels in patients developing neither venous thromboembolism nor major intercurrent illness. Blood Coagul Fibrinolysis 2003; 14: 639-645.
47. Kelly J., Rudd A., Lewis R.R., et al. Screening for proximal deep vein thrombosis after acute ischemic stroke: a prospective study using clinical factors and plasma D-dimers. J Thromb Haemost 2004; 2: 1321-1326.
48. Takagi K., Ginsberg M.D., Globus M.Y, et al. Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbral region following middle cerebral artery occlusion in the rat: correlation with histopathology. J Cereb Blood Flow Metab 1993; 13: 575-595.
49. Tzschentke TM. Glutamatergic mechanisms in different disease states: overview and therapeutical implications - an introduction. Amino Acids 2002; 23: 147-152.
50. Martinez F., Castillo J., Leira R., et al. Taurine levels in plasma and cerebrospinal fluid in migraine patients. Headache 1993; 33: 324-327.
51. Saransaari P., Oja S.S. Ischemia-induced taurine release is modified by nitric oxide-generating compounds in slices from the developing and adult mouse hippocampus. Neurochem Res 2002; 27: 395-402.
52. Sardo P., Ferraro G. Modulatory effects of nitric oxide-active drugs on the anticonvulsant activity of lamotrigine in an experimental model of partial complex epilepsy in the rat. BMC Neurosci 2007; 8: 47.